Literature DB >> 30611908

Daily oral dosing of vitamin D3 using 5000 TO 50,000 international units a day in long-term hospitalized patients: Insights from a seven year experience.

Patrick J McCullough1, Douglas S Lehrer2, Jeffrey Amend3.   

Abstract

Vitamin D3 is a secosteroid hormone produced in the skin in amounts estimated up to 25,000 international units (IUs) a day by the action of UVB radiation on 7-dehydrocholesterol. Vitamin D deficiency is common due to both lack of adequate sun exposure to the skin, and because vitamin D is present in very few food sources. Deficiency is strongly linked to increased risk for a multitude of diseases, several of which have historically been shown to improve dramatically with either adequate UVB exposure to the skin, or to oral or topical supplementation with vitamin D. These diseases include asthma, psoriasis, rheumatoid arthritis, rickets and tuberculosis. All patients in our hospital have been routinely screened on admission for vitamin D deficiency since July 2011, and offered supplementation to either correct or prevent deficiency. During this time, we have admitted over 4700 patients, the vast majority of whom agreed to supplementation with either 5000 or 10,000 IUs/day. Due to disease concerns, a few agreed to larger amounts, ranging from 20,000 to 50,000 IUs/day. There have been no cases of vitamin D3 induced hypercalcemia or any adverse events attributable to vitamin D3 supplementation in any patient. Three patients with psoriasis showed marked clinical improvement in their skin using 20,000 to 50,000 IUs/day. Analysis of 777 recently tested patients (new and long-term) not on D3 revealed 28.7% with 25-hydroxyvitaminD3 (25OHD3) blood levels < 20 ng/ml, 64.1% < 30 ng/ml, a mean 25OHD3 level of 27.1 ng/ml, with a range from 4.9 to 74.8 ng/ml. Analysis of 418 inpatients on D3 long enough to develop 25OHD3 blood levels > 74.4 ng/ml showed a mean 25OHD3 level of 118.9 ng/ml, with a range from 74.4 to 384.8 ng/ml. The average serum calcium level in these 2 groups was 9.5 (no D3) vs 9.6 (D3), with ranges of 8.4 to 10.7 (no D3) vs 8.6 to 10.7 mg/dl (D3), after excluding patients with other causes of hypercalcemia. The average intact parathyroid hormone levels were 24.2 pg/ml (D3) vs. 30.2 pg/ml (no D3). In summary, long-term supplementation with vitamin D3 in doses ranging from 5000 to 50,000 IUs/day appears to be safe.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adverse events; Intact parathyroid hormone; Long-term supplementation

Mesh:

Substances:

Year:  2019        PMID: 30611908     DOI: 10.1016/j.jsbmb.2018.12.010

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  22 in total

Review 1.  Vitamin D and musculoskeletal health: outstanding aspects to be considered in the light of current evidence.

Authors:  Marcela Moraes Mendes; Patricia Borges Botelho; Helena Ribeiro
Journal:  Endocr Connect       Date:  2022-09-26       Impact factor: 3.221

2.  Beneficial Effect of Short-Term Supplementation of High Dose of Vitamin D3 in Hospitalized Patients With COVID-19: A Multicenter, Single-Blinded, Prospective Randomized Pilot Clinical Trial.

Authors:  Miguel Cervero; Daniel López-Wolf; Guiomar Casado; Maria Novella-Mena; Pablo Ryan-Murua; María Luisa Taboada-Martínez; Sara Rodríguez-Mora; Lorena Vigón; Mayte Coiras; Montserrat Torres
Journal:  Front Pharmacol       Date:  2022-07-04       Impact factor: 5.988

Review 3.  Oral and Topical Vitamin D, Sunshine, and UVB Phototherapy Safely Control Psoriasis in Patients with Normal Pretreatment Serum 25-Hydroxyvitamin D Concentrations: A Literature Review and Discussion of Health Implications.

Authors:  Patrick J McCullough; William P McCullough; Douglas Lehrer; Jeffrey B Travers; Steven J Repas
Journal:  Nutrients       Date:  2021-04-29       Impact factor: 5.717

4.  Impact of daily high dose oral vitamin D therapy on the inflammatory markers in patients with COVID 19 disease.

Authors:  Maheshwar Lakkireddy; Srikanth Goud Gadiga; R D Malathi; Madhu Latha Karra; I S S V Prasad Murthy Raju; Sangeetha Chinapaka; K S S Sai Baba; Manohar Kandakatla
Journal:  Sci Rep       Date:  2021-05-20       Impact factor: 4.996

Review 5.  Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths.

Authors:  William B Grant; Henry Lahore; Sharon L McDonnell; Carole A Baggerly; Christine B French; Jennifer L Aliano; Harjit P Bhattoa
Journal:  Nutrients       Date:  2020-04-02       Impact factor: 5.717

6.  Association of Vitamin D Levels, Race/Ethnicity, and Clinical Characteristics With COVID-19 Test Results.

Authors:  David O Meltzer; Thomas J Best; Hui Zhang; Tamara Vokes; Vineet M Arora; Julian Solway
Journal:  JAMA Netw Open       Date:  2021-03-01

Review 7.  The Benefits of Vitamin D Supplementation for Athletes: Better Performance and Reduced Risk of COVID-19.

Authors:  William B Grant; Henry Lahore; Michelle S Rockwell
Journal:  Nutrients       Date:  2020-12-04       Impact factor: 5.717

Review 8.  A Review of the Relationship Between Vitamin D and Parkinson Disease Symptoms.

Authors:  Michelle E Fullard; John E Duda
Journal:  Front Neurol       Date:  2020-05-27       Impact factor: 4.003

9.  Vitamin D Clinical Pharmacology: Relevance to COVID-19 Pathogenesis.

Authors:  Paige-Ashley Campbell; Mimi Wu Young; Raphael C Lee
Journal:  J Natl Med Assoc       Date:  2020-11-02       Impact factor: 1.798

Review 10.  Vitamin D supplementation as a rational pharmacological approach in the COVID-19 pandemic.

Authors:  León Ferder; Virna Margarita Martín Giménez; Felipe Inserra; Carlos Tajer; Laura Antonietti; Javier Mariani; Walter Manucha
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-09-30       Impact factor: 5.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.